Pharmacological management of erectile dysfunction

BJU International

Volumn 91, Issue 5, 2003, Pages 446-454

  Montorsi, F ^a   Salonia, A ^a   Deho', F ^a   Cestari, A ^a   Guazzoni, G ^a   Rigatti, P ^a   Stief, C ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; PHOSPHODIESTERASE; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL; VASOACTIVE AGENT;

CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; PRIORITY JOURNAL; REVIEW; RHINITIS; SEXUAL BEHAVIOR; TREATMENT PLANNING; VERTIGO; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ALPROSTADIL; APOMORPHINE; CARBOLINES; DRUG COMBINATIONS; HUMANS; IMIDAZOLES; IMPOTENCE; INJECTIONS; MALE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 0037349838     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04093.x     Document Type: Review

References (52)

1. Meuleman E, Broderick G, Meng Tan H et al. Clinical evaluation and the doctor-patient dialogue. In Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R eds, Erectile Dysfunction. Plymouth UK: Health Publication Ltd, 2000: 115-38
2. Jardin A, Wagner G, Khouri S et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. In Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R eds, Erectile Dysfunction. Plymouth UK: Health Publication Ltd, 2000: 709-28
3. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14 (Suppl. 1): S43-S52
4. Steers W. Viagra after one year. Urology 1999; 54: 12-7
5. Rosen RC, Riley A, Wagner G. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
6. Moore RA, Edwards JE, McQuay HJ. Sildenafil (Viagra) for male erectile dysfunction. a meta analysis of clinical trial reports. MBC Urol 2002; 2: 6
7. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793-7
8. Zippe CD, Jhaveri FM, Klein EA et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241-5
9. Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1999; 11 (Suppl. 11): S15-S22
10. Lowentritt BH. Sildenafil citrate after radical retropubic prostatectomy. Urology 2000; 55: 241-5
11. Giuliano F, Montorsi F, Mirone V, Rossi D, Sweeney M. Switching from intracavernous prostagtandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction. results of a multicenter European study. J Urol 2000; 164: 708-11
12. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy. efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197-200
13. Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshurtz LI, Kim ED. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474-6
14. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002; 287: 719-25
15. Fox K, Thadani U, Ma PTS, Nash SD, Keltai M. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate. Circulation 2001; 104 (Suppl. II): 601
16. Paige NM, Hays RD, Litwin MS, Rajfer J, Shapiro MF. Improvement in emotional well being and relationships of users of sildenafil. J Urol 2001; 166: 1774-8
17. Rampin O. Mode of action of a new oral treatment for erectile dysfunction: apomorphine SL. BJU Int 2001; 88 (Suppl. 3): 22-4
18. Mirone VG, Stief CG. Efficacy of apomorphine SL in erectile dysfunction. BJU Int 2001; 88 (Suppl. 3): 25-9
19. Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-64
20. Heaton JP, Dean J, Sleep DJ. Sequential administration enhances the effect of apomorphine in men with erectile dysfunction. Int J Impot Res 2002; 14:61-4
21. Buvat J, Montorsi F. Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int 2001; 88 (Suppl. 3): 30-5
22. Stark S, Sachse R, Liedl T et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-90
23. Klotz T, Sachse R, Heidrich A et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 32-9
24. Porst H, Rosen R, Padma-Nathan H et al. The efficacy and tolerability of vardenafil, a new, oral selective PDE-5 inhibitor, in patients with erectile dysfunction: first at-home clinical trial. Int J Impot Res 2001; 13: 192-9
25. Pryor JP. Vardenafil: update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 1): S65-S69
26. Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins V, Pullman W. Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). J Urol 2001; 165 (Suppl): A923
27. Padma-Nathan H, McMurray JG, Pullman WE et al. On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2-9
28. Porst H. Daily IC351 treatment of ED. Int J Impot Res 2000; 12 (Suppl. 3): S76, A-B13
29. Saenz de Tejada I, Emmick J, Anglin G, Fredlund P, Pullman W. The effect of asneeded tadalafil (IC351) treatment of erectile dysfunction in men with diabetes. Int J Impot Res 2001; 13 (Suppl. 4): A128
30. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001; 13 (Suppl. 4): A120
31. Porst H. Ic351 (tadalafil, cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 1): S57-S64
32. Montorsi F, Guazzoni G, Rigatti P, Pozza G. Pharmacological management of erectile dysfunction. Drugs 1995; 50: 465-79
33. Montorsi F, Guazzoni G, Bergamaschi F. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol 1993; 149: 1291-5
34. Montorsi F, Guazzoni G, Bergamaschi F. Intracavernous vasoactive pharmacotherapy. the impact of a new self-injection device. J Urol 1993; 150: 1829-32
35. Zentgraf M, Baccouche M, Junemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int 1988; 43: 65-8
36. Leungwattanakij L, Flynn V, Hellstrom WJG. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin N Am 2001; 28: 343-54
37. Montorsi F, Salonia A, Zanoni M et al. Current status of local penile therapy. Int J Impot Res 2002; 14 (Suppl. 1): S70-S81
38. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994; 43: 844-7
39. 1 therapy modify the intracavernous musculature? J Urol 2000; 163: 464-6
40. Brock G, Mai Tu L, Linet O. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Int J Impot Res 2001; 57: 536-41
41. Maniam P, Seftel A, Corty E. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy. J Urol 2001; 165: 830-3
42. Shabsigh R, Padma Nathan H, Gittleman M. Intracavernous Alprostadil Alfadex is effective and safe in patients with erectile dysfunction after failing sildenafil. Urology 2000; 55: 477-80
43. Vardi Y, Saenz de Tejada I. Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis. Urology 1997; 49: 749-52
44. Lewis R. Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 4): S86-S90
45. Williams G, Abbou CC, Amar ET. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998; 81: 889-94
46. Fulgham PF, Cochran JS, Denman JL. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998; 160: 2041-6
47. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000; 38: 30-4
48. Mydlo JH, Volpe MA, Macchia RJ. Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int 2000; 86: 469-73
49. Shabsigh R, Padma Nathan H, Gittleman M. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: a comparative, randomised, crossover, multicenter study. Urology 2000; 55: 109-13
50. Porst H. Transurethral alprostadil with MUSE (vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187-92
51. Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomised study. BJU Int 1999; 83: 812-5
52. Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring non-invasive therapy. Int J Impot Res 2002; 14 (Suppl. 1): 38-42